EVM 16 / Everest Medicines - LARVOL DELTA

EVM16CX01: EVM16 Injection As a Single and Combination with Tislelizumab in Solid Tumors (clinicaltrials.gov) - P1 | N=78 | Recruiting | Sponsor: Peking University | Not yet recruiting ➔ Recruiting | Initiation date: Nov 2024 ➔ Mar 2025

Enrollment open • Trial initiation date • Oncology • Solid Tumor

Everest Medicines Announces First Patient Dosed with EVM16, Its First Internally Developed Personalized mRNA Cancer Vaccine (PRNewswire) - "Everest Medicines...announced that the first patient has been dosed with the Company's internally developed personalized mRNA cancer vaccine EVM16 at Peking University Cancer Hospital in the investigator-initiated clinical trial (IIT) EVM16CX01. EVM16CX01 is the first-in-human (FIH) trial for EVM16, conducted jointly at Peking University Cancer Hospital and Fudan University Shanghai Cancer center, to assess the safety, tolerability, immunogenicity, and preliminary efficacy of EVM16 as a monotherapy and in combination with a PD-1 antibody in patients with advanced or recurrent solid tumors."

Trial status • Solid Tumor

Everest Medicines Announces the Initiation of an Investigator-Initiated Clinical Trial (IIT) for Personalized mRNA Cancer Vaccine Program EVM16 (PRNewswire) - "Everest Medicines...announced the launch of an Investigator-Initiated Clinical Trial (IIT) for a personalized mRNA cancer vaccine, EVM16, under the study EVM16CX01, at the Peking University Cancer Hospital and Fudan University's Cancer Hospital. This trial is designed to assess the safety, tolerability, immunogenicity, and preliminary efficacy of EVM16 injection as a monotherapy and in combination with PD-1 antibody for patients with advanced or recurrent solid tumors. EVM16CX01 is the first-in-human (FIH) trial for EVM16."

Trial status • Solid Tumor

EVM16 Injection as a Single and Combination With Tislelizumab in Solid Tumors (clinicaltrials.gov) - P1 | N=78 | Not yet recruiting | Sponsor: Peking University

Metastases • New P1 trial • Oncology • Solid Tumor